ClinicalTrials.gg
CompletedNCT07645495FREMSUpdated Nov 12, 2026

Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.

An interventional study of FREMS in Chronic Ulcers, sponsored by Beni-Suef University. Completed at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Ulcer with a site in Egypt — 3 open to participants now, 3 under way, 1 of them phase 3. Ulcer · Egypt.

Enrollment
17th of 20
26 · median 38
Started
2026
with 1 other
No phase
14 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Beni-Suef University

Among the 22 studies in Ulcer with a site in Egypt, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 22nd registered.

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

3 of the 22 studies in Ulcer with a site in Egypt are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Ulcer with a site in Egypt, or all of them as a file.
02

Study summary

The goal of the study is to

  1. To measure wound size of chronic ulcers after using FREMS therapy and phenytoin application in the interventional group monthly till the end of the third month compared to baseline.
  2. To measure wound size of chronic ulcers after using standard of care in control group monthly till the end of the third month compared to baseline.
  3. To compare the results of the 2 groups and determine the significance of the treatment.
Read the detailed description

Wound ulcers including diabetic foot ulcers impose a substantial and escalating economic burden on healthcare systems worldwide. In the United States alone, chronic wounds affect over 10 million people and account for annual healthcare costs ranging from $28.1 to $96.8 billion. Major challenges persist, including antibiotic resistance, high recurrence rates, delayed healing in patients with comorbidities, and limited evidence for many advanced therapies. Additionally, cost, access to specialized care, and the need for individualized, multidisciplinary management remain significant barriers to optimal outcomes. Using two effective modalities in cases that are resistant to all known treatments, whether they are conservative or adjuvant, is a promising technique to end the entrapment of a wound in a certain stage and avoid complications like further amputation. enrolled patients will be randomly assigned to one of either groups Group A: Intervention group that will receive 3 sessions /week of FERM with phenytoin application with spraying phenytoin topical 40 mg spray after each session according to ulcer size to cover the ulcer.

Group B: Control group that will receive standard of care and will be assessed at baseline and every month till they completed 3 months of treatment.

03

Conditions studied

  • Chronic Ulcers

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chronic ulcers more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • incapable of being in the clinic of diabetic ulcer during treatment period 3 days/ week for 3 months.
  • severe ischemia that is indicated for a surgery.
  • infection or osteomyelitis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    chronic ulcers patients

    FREMS therapy 3 sessions/week for 40 minutes with phenytoin spray 40mg.

    Device: FREMS

  • No intervention
    ulcers patients

    control group: SOC(debridement and basic wound care)

Interventions

  • DeviceFREMS

    frequency rhythmic electrical stimulation which is an electrical device specialized in diabetes complications like ulcers and neuropathies, with proven efficacy in neuropathies, and promising results in ulcers.

06

What researchers measure

Primary outcomes

  1. healing rate

    wound size

    Time frame: measuring once a month for 3 months.

07

Study locations

1 site
  • National diabetes institute
    Giza, Egypt
08

References and documents

Publications

  • Magnoni C, Rossi E, Fiorentini C, Baggio A, Ferrari B, Alberto G. Electrical stimulation as adjuvant treatment for chronic leg ulcers of different aetiology: an RCT. J Wound Care. 2013 Oct;22(10):525-6, 528-33. doi: 10.12968/jowc.2013.22.10.525. PubMed 24142074 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

Of 44 non-industry interventional studies with no phase under Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 64. This study's 2 months is below that.

Counting every sponsor, half of 69 studies reached it within 25 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 12, 2026
StartActual
Jul 1, 2026
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Completed
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645495
Collaborators
General Organization for Teaching Hospitals and Institutes
Responsible party
Ibtihal Nassar (physiotherapist., Beni-Suef University) — Principal investigator
First posted
Jun 12, 2026
Start date
Jul 1, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion